Lifetime heart failure risk*

Slides:

Advertisements

Similar presentations

Participant Characteristics by Lowest Leg AAI Category Ann M. O’Hare, et al, Circulation 2006;113;

Advertisements

Rosuvastatin 10 mg n=2514 Placebo n= to 4 weeks Randomization 6weeks3 monthly Closing date 20 May 2007 Eligibility Optimal HF treatment instituted.

Date of download: 6/3/2016 Copyright © The American College of Cardiology. All rights reserved. From: Relationship Between Operator Volume and Adverse.

Chronotropic Incompetence by Peter H. Brubaker, and Dalane W. Kitzman Circulation Volume 123(9): March 8, 2011 Copyright © American Heart Association,

Discontinuation of medication after nonfatal event: MI

Fig ACCF/AHA Guideline for the management of heart failure

Flow of Individuals Through the Vitamin E and Vitamin C Components of the Physicians’ Health Study II Howard D. Sesso et al. JAMA 2008;300:

Copyright © 2015 by the American Osteopathic Association.

Supplementary Figure 4. Kaplan-Meier curves of 12-month readmission free survival rates according to renal dysfunction with subclassification in all (A),

Plasma Vitamin C, but Not Vitamin E, Is Associated With Reduced Risk of Heart Failure in Older MenClinical Perspective by Sasiwarang Goya Wannamethee,

Current and future paradigm for prognostication and testing of therapeutics in patients with heart failure using machine learning. Current and future paradigm.

Clyde W. Yancy et al. JACC 2017;70:

Figure 1 Energy supply–demand matching in health and heart failure

Nat. Rev. Cardiol. doi: /nrcardio

A. Heart failure: A challenge to the healthcare delivery system

Nat. Rev. Cardiol. doi: /nrcardio

Nat. Rev. Cardiol. doi: /nrcardio

Shadi Al Halabi et al. JACEP 2015;1:

Figure 4 Prevalence of HFpEF and HFrEF by age

Nat. Rev. Cardiol. doi: /nrcardio

Dileep Raman et al. JACEP 2017;3:

Sudden Unexpected Death in North Carolina (SUDDEN) Gender and Ethnicity by Age—the majority of the cohort is over age 55 years, especially black men but.

Mirnela Byku, and Douglas L. Mann BTS 2016;1:95-106

Nat. Rev. Cardiol. doi: /nrcardio

Effect of PCI on 1-year risk of all-cause mortality and major cardiovascular outcomes. CABG, coronary artery bypass grafting; CI, confidence interval (bars);

John E. Sanderson JCHF 2014;2:93-94

P2Y12 blockade versus placebo; risk ratio with 95% CIs for the primary composite end point of cardiovascular death, non-fatal myocardial infarction and.

Non-cardiovascular comorbidity, severity and prognosis in non-selected heart failure populations: A systematic review and meta-analysis C.A. Rushton,

Further exploration of the risk factor associations with either the first or subsequent congestive heart failure (CHF) events using the Prentice, Williams,

Factors independently associated with odds of fractures

David J.A. Jenkins et al. JACC 2018;71:

Flow chart of the study population according to thienopyridines used in the FAST-MI registry in patients with STEMI and NSTEMI. FAST-MI, French Registry.

Distribution of Cardiovascular Risk Factors by Baseline CRP Concentration M. Cushman et al. Circulation. 2005;112:25-31.

Baseline Characteristics According to Sex

Romain Gallet et al. BTS 2016;1:14-28

Romain Gallet et al. BTS 2016;1:14-28

Baseline Demographic Characteristics of Adults With Diagnosed Heart Failure and Eligible to Receive Lipid-Lowering Therapy Alan S. Go, et al.

Receiver operating characteristic curves for the association of primary outcome using each clinical risk score and each clinical risk score adjusted for.

Time to death from diabetes diagnosis for propensity-matched sample adjusted for age, gender, race, and other conditions. Time to death from diabetes diagnosis.

Andris Kazmers, MD, Manuel D. Cerqueira, MD, R.Eugene Zierler, MD

An ACCORD BP sub-analysis HR: 1.06; 95%CI: ; P=0.61

Flow chart of search strategy

Kaplan–Meier plots of 5 and 12-year all cause (A and C, respectively) and cardiovascular mortality (B and D, respectively) with number of participants.

T2DM patients with HF may benefit from SGLT2 inhibitor therapy

Supplementary Figure 4. Kaplan-Meier curves of 12-month readmission free survival rates according to renal dysfunction with subclassification in all (A),

Figure 3. Survival rates according to renal dysfunction

EMPA-REG OUTCOME: Cumulative incidence of the primary outcome

Absolute mortality difference Change in LVEF from baseline

Associations between type of MI and incident HF

An ACCORD BP sub-analysis HR: 1.06; 95%CI: ; P=0.61

Multivariate Cox survival analysis with predictors of mortality after adjusting for comorbidities and DBT. COPD, chronic obstructive pulmonary disease;

Genetic predisposition to CHD modifies the increased CHD risk associated with smoking (*) ORs adjusted for age, gender, total energy intake, alcohol intake,

Steven R. Steinhubl, and Eric J. Topol JACC 2015;66:

MRRs and EMRRs for women with ACS

The benefit of evolocumab treatment is consistent regardless of inflammation level HR %CI ARR 1.6% 1.8%

Christian Madelaire et al. JCHF 2018;6:

Ticagrelor versus prasugrel; risk ratio with 95% CIs for the primary composite end point, primary composite end point in those undergoing PCI, myocardial.

William T. Abraham et al. JCHF 2018;j.jchf

Effect of PCI on 3 to 5-year risk of all-cause mortality and major cardiovascular outcomes. CABG, coronary artery bypass grafting; CI, confidence interval.

Percentage distribution of ESC HF subtypes and no cardiac dysfunction (no dysf, n=38) among all 370 included patients, where HFvhd is HF due to valvular.

Increase of physical activity over time associated with lower HF risk

Prasugrel versus clopidogrel; risk ratio with 95% CIs for the primary composite end point of cardiovascular death, non-fatal myocardial infarction and.

Multivariable-adjusted HRs and 95% CIs for outcomes for waist circumference. Multivariable-adjusted HRs and 95% CIs for outcomes for waist circumference.

Prasugrel and ticagrelor versus clopidogrel; risk ratio with 95% CIs for the primary composite end point of cardiovascular death, non-fatal myocardial.

Constantijn Franssen et al. JCHF 2016;4:

Adjusted cumulative incidence of stroke, by sex and heart failure status. Adjusted cumulative incidence of stroke, by sex and heart failure status. The.

Adjusted associations between hypertensive disorder of pregnancy subtypes and MI, heart failure and stroke. Adjusted associations between hypertensive.

Associations of dialysis session length with mortality and hospitalizations. Associations of dialysis session length with mortality and hospitalizations.

Relationship between 6-month all-cause mortality and the three types of heart failure adjusted for age ≥75 years, peripheral edema at admission, systolic.

Adjusted cumulative disability incidence by sex and heart failure status. Adjusted cumulative disability incidence by sex and heart failure status. The.

Presentation transcript:

Lifetime heart failure risk* Lifetime Risk (%, 95%CI) Women Men HF overall 23.8 (22.4-25.1) 27.4 (25.9-29.0) HFpEF 10.7 (9.6-11.8) 10.4 (9.1-11.6) HFrEF 5.8 (5.03-6.6) 10.6 (9.4-11.8) Lifetime Risk (%, 95%CI) Non-black Black HF overall 25.9 (24.8-27.0) 22.4 (20.1-24.6) HFpEF 11.2 (10.2-12.1) 7.7 (6.0-9.4) HFrEF 7.9 (7.1-8.7) 7.7 (6.1-9.2) Lifetime Risk (%, 95%CI) MI No MI HF overall 53.7 (50.9-56.5) 20.0 (19.0-21.0) HFpEF 20.9 (18.4-23.4) 8.5 (7.6-9.3) HFrEF 20.0 (17.6-22.5) 5.3 (4.7-6.0) *Stratified by gender, race and previous MI, at the age of 45 CI: confidence interval; HF: heart failure; HFpEF: heart failure with preserved ejection fraction; HFrEF: heart failure with reduced ejection fraction; MI: myocardial infarction Pandey A, et al. Circulation 2018